Medpace Holdings Inc. (MEDP)
NASDAQ: MEDP · Services-Commercial Physical & Biological Research · Cincinnati, OH
Our rating: Neutral
Call changed from Positive to Neutral at $669.20, moderate conviction, October 23, 2026.
Breaks if: The Neutral call turns Cautious if Medpace reports revenue growth below 12% in two consecutive quarterly filings — a signal the biotech funding cycle has tightened enough to undercut the growth premium the 43.8× multiple depends on. It turns Positive if the stock pulls back 20% or more from current levels without a parallel deterioration in backlog or operating margin over the same period.
Key figures
| Market value | $17.1B |
|---|---|
| Revenue, last 12 months | $2.8B |
| Net income, last 12 months | $518M |
| Free cash flow, last 12 months | $668M |
| Price to earnings | 33.0× |
| Free cash flow yield | 3.9% |
| Dividend yield | 0.0% |
| Operating margin | 21.4% |
| Return on equity | 117.9% |
| Beta to the S&P 500 | 0.93 |
| Volatility, annualized | 54.4% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $716M | 8.5% | $4.84 | $196M |
| June 30, 2026 | $707M | 17.2% | $4.25 | $138M |
| March 31, 2026 | $707M | 26.5% | $4.28 | $145M |
| December 31, 2025 | $708M | 32.0% | $4.64 | $188M |
| September 30, 2025 | $660M | 23.7% | $3.86 | $235M |
| June 30, 2025 | $603M | 14.2% | $3.10 | $142M |
| March 31, 2025 | $559M | 9.3% | $3.67 | $116M |
| December 31, 2024 | $537M | 7.7% | $3.67 | $183M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $0.86B: Claude 8%, Gemini 15%, Mistral 20%
- Diluted earnings per share are at least $4.64: Claude 45%, Gemini 90%, Mistral 48%
- Free cash flow for the quarter is at least $0.19B: Claude 52%, Gemini 70%, Mistral 50%
- Backlog at the end of the quarter is at least $3.80B: Claude 38%, Gemini 75%, Mistral 58%
11 ledger entries and 34 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.